汇宇制药(688553.SH)通过美国FDA现场检查

Core Viewpoint - The company, Huyou Pharmaceutical, successfully passed the FDA's current Good Manufacturing Practice (cGMP) inspection and Pre-Approval Inspection (PAI), which is crucial for its operations in the U.S. market [1] Group 1: FDA Inspection Results - The company underwent the FDA inspection from October 27, 2025, to November 6, 2025, and received the Establishment Inspection Report (EIR) confirming the completion of the inspection [1] - This inspection marks the third time the company has been evaluated by the FDA, indicating a consistent compliance with regulatory standards [1] Group 2: Impact on Business Operations - The successful completion of the cGMP and PAI inspections ensures that the company's production lines for anti-tumor injectables and active pharmaceutical ingredients meet FDA requirements [1] - This achievement is expected to positively influence the company's future operating performance and enhance its competitiveness in international markets [1] - The inspection results provide a solid foundation for the company's ongoing expansion in the U.S. market, supporting its sustainable and healthy development [1]